BioCART

  • Research type

    Research Study

  • Full title

    An integrated multiomic and spectroscopic approach to the identification of new CAR-T biomarkers (BioCART) in blood using machine learning analysis

  • IRAS ID

    340403

  • Contact name

    Siang Boon Koh

  • Contact email

    siangboon.koh@bristol.ac.uk

  • Sponsor organisation

    University of Bristol

  • Duration of Study in the UK

    5 years, 0 months, 1 days

  • Research summary

    Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the outcome for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with reports of 40-60% complete remission in otherwise incurable patients. Despite these remarkable results the wider uptake of CART therapy is hindered by development of resistance and life-threatening toxicities such as cytokine release syndrome (CRS) and/or neurotoxicity. There is therefore a clear clinical need for biomarkers to efficiently monitor and manage the development of toxicities and disease progression.

    Although several projects have used a transcriptomic/genomic approach to biomarker discovery in CART patients, either cellularly or in cell free DNA/RNA, to date these studies have used a single omic approach and nearly always with a small number of patients.

    Our objective is to use a multi-omic techniques (including circulating tumour DNA, miRNA, methylomic, glycomic and spectroscopic) to identify novel blood based biomarkers in B-cell lymphoma patients treated with CART in a multi-centre international prospective study.

  • REC name

    London - Surrey Borders Research Ethics Committee

  • REC reference

    24/PR/0829

  • Date of REC Opinion

    16 Jul 2024

  • REC opinion

    Favourable Opinion